FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.marketwatch.com — the content belongs to MarketWatch.
